Insights into the transcriptomic heterogeneity of brain endothelial cells in normal aging and Alzheimer’s disease
Open Access
- 16 December 2024
- journal article
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (2) , 569-576
Abstract
Drug development for Alzheimer’s disease is extremely challenging, as demonstrated by the repeated failures of amyloid-β-targeted therapeutics and the controversies surrounding the amyloid-β cascade hypothesis. More recently, advances in the development of Lecanemab, an anti-amyloid-β monoclonal antibody, have shown positive results in reducing brain A burden and slowing cognitive decline in patients with early-stage Alzheimer’s disease in the Phase III clinical trial (Clarity Alzheimer’s disease). Despite these promising results, side effects such as amyloid-related imaging abnormalities (ARIA) may limit its usage. ARIA can manifest as ARIA-E (cerebral edema or effusions) and ARIA-H (microhemorrhages or superficial siderosis) and is thought to be caused by increased vascular permeability due to inflammatory responses, leading to leakages of blood products and protein-rich fluid into brain parenchyma. Endothelial dysfunction is an early pathological feature of Alzheimer’s disease, and the blood–brain barrier becomes increasingly leaky as the disease progresses. In addition, APOE4, the strongest genetic risk factor for Alzheimer’s disease, is associated with higher vascular amyloid burden, increased ARIA incidence, and accelerated blood–brain barrier disruptions. These interconnected vascular abnormalities highlight the importance of vascular contributions to the pathophysiology of Alzheimer’s disease. Here, we will closely examine recent research evaluating the heterogeneity of brain endothelial cells in the microvasculature of different brain regions and their relationships with Alzheimer’s disease progression.Keywords
This publication has 35 references indexed in Scilit:
- Integrative multi-omic profiling of adult mouse brain endothelial cells and potential implications in Alzheimer’s diseaseCell Reports, 2023
- The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s diseaseMolecular Therapy, 2022
- Diverse human astrocyte and microglial transcriptional responses to Alzheimer’s pathologyActa Neuropathologica, 2021
- Role of Notch signaling in neurovascular aging and Alzheimer’s diseaseSeminars in Cell & Developmental Biology, 2020
- Mapping the Fine-Scale Organization and Plasticity of the Brain VasculatureCell, 2020
- Functional morphology of the blood–brain barrier in health and diseaseActa Neuropathologica, 2018
- Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's diseaseNeurobiology of Aging, 2015
- The APOE ε4/ε4 Genotype Potentiates Vascular Fibrin(Ogen) Deposition in Amyloid-Laden Vessels in the Brains of Alzheimer's Disease PatientsJournal of Cerebral Blood Flow & Metabolism, 2013
- Endothelial cell heterogeneity of blood‐brain barrier gene expression along the cerebral microvasculatureJournal of Neuroscience Research, 2009
- Differentiation of endothelial cells: Analysis of the constitutive and activated endothelial cell phenotypesBioEssays, 1994